-
Mashup Score: 3FDA Approves Cabozantinib for Pancreatic and Extra-Pancreatic Neuroendocrine Tumors - 2 month(s) ago
The FDA has approved cabozantinib (Cabometyx) for use in select patients with pancreatic and extra-pancreatic neuroendocrine tumors.
Source: www.onclive.comCategories: General Medicine NewsTweet
-
Mashup Score: 0Ceftobiprole Receives FDA Approval, Enhancing Antibiotic Options - 1 year(s) ago
Dr. Thomas Holland discusses the breakthrough in antibiotic development.
Source: www.contagionlive.comCategories: General Medicine News, Infectious DiseaseTweet-
Dr. Thomas Holland discusses the FDA-approved antibiotic Ceftobiprole for treating Staphylococcus aureus bacteremia. #FDAapproval https://t.co/wRSOkzlYVz https://t.co/SY1wky9AC9
-
-
Mashup Score: 6FDA Grants Orphan Drug Designation to ‘1104, First-In-Class Peptide for Eosinophilic Esophagitis - 1 year(s) ago
The designation offers support in developing potential new medicines, treatment, and diagnosis to prevent rare conditions, like EoE.
Source: www.pharmacytimes.comCategories: General Medicine News, General Journals & SocietTweet-
The FDA has granted Orphan Drug Designation to ‘1104, a first-in-class immune-resetting peptide (Revolo Biotherapeutics) designed to treat eosinophilic esophagitis. #FDAapproval Read More: https://t.co/5GyMBjwJyv
-
-
Mashup Score: 2FDA Approves IgG-Hyaluronidase Recombinant for the Treatment of Adult Patients With CIDP - 1 year(s) ago
Previously, IgG-hyaluronidase recombinant was approved by the FDA in 2014 for the treatment of primary immunodeficiency in adult patients and has expanded to include some pediatric patients.
Source: www.pharmacytimes.comCategories: General Medicine News, General Journals & SocietTweet-
The FDA approves Hyqvia for chronic inflammatory demyelinating polyneuropathy maintenance therapy, marking a milestone in neuroimmunological treatment, showcasing potential alternatives to IVIG infusions. #FDAApproval Read More: https://t.co/aHZrs7PNIT
-
-
Mashup Score: 7
The approval marks the first authorized at-home sample collection test for sexually transmitted diseases.
Source: www.pharmacytimes.comCategories: General Medicine News, PayerTweet-
FDA grants approval for the LetsGetChecked Simple 2 at-home collection system, the first FDA-authorized home sample collection kit for chlamydia and gonorrhea. #FDAapproval Read More: https://t.co/7BDBvmihMf
-
-
Mashup Score: 1Retinal Physician - September 2023 AMD Issue - 2 year(s) ago
Speakers: Drs. Jay Sridhar, Katherine Talcott, Joshua Uhr, and Akshay Thomas Listen now
Source: www.retinalphysician.comCategories: Latest Headlines, OphthalmologyTweet-
Jay Sridhar, MD, and his guests Drs. Talcott, Uhr, and Thomas discuss the September issue of Retinal Physician in episode 403 of the Retina Podcast. Find the episode at https://t.co/W8AlWgcEtM #FDAapproval #ophthalmology #EyleaHD #maculardegeneration https://t.co/jJqqE5KeuL
-
-
Mashup Score: 1
The Food and Drug Administration has approved Daxxify (DaxibotulinumtoxinA-lanm; Revance Therapeutics, Nashville, TN) for its first therapeutic indica
Source: practicalneurology.comCategories: Latest Headlines, NeurologyTweet-
https://t.co/Nb3bXZZxWE @revance #FDAApproval #Daxxify #Dystonia
-
-
Mashup Score: 1FDA Grants Accelerated Approval to Talquetamab for Patients With R/R Multiple Myeloma - 2 year(s) ago
On August 9, 2023, the FDA granted accelerated approval to talquetamab for adult patients with relapsed/refractory MM who received 4 or more prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody.
Source: www.hmpgloballearningnetwork.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Exciting news! On August 9, 2023, the #FDA granted accelerated approval to #talquetamab for the treatment of adult patients with R/R #MultipleMyeloma. Learn more: https://t.co/4SHUwEmXgs #MM #FDAApproval #OncologyNews @FDAOncology https://t.co/AVtUbiQm4y
-
-
Mashup Score: 1FDA approves pralsetinib for lung cancer with RET gene fusions - 2 year(s) ago
FDA approves pralsetinib for lung cancer with RET gene fusions
Source: www.fda.govCategories: Hem/Oncs, Latest HeadlinesTweet-
🎉 Exciting News! 🚀 #Pralsetinib has just secured FDA approval for adult patients with metastatic RET fusion-positive #NSCLC. 🫁🧬 #precisionmedicine #FDAApproval #LungCancerRET #MedTwitter #lcsm https://t.co/1SWNc0fgAv
-
-
Mashup Score: 0
The FDA converted the novel drug Leqembi, the first therapy proven to slow the course of Alzheimer disease, to full approval.
Source: Docwire NewsCategories: Latest Headlines, Partners & KOLsTweet-
Significant news. This week FDA converted the novel drug Leqembi, the first therapy proven to slow the course of Alzheimer disease, to full approval. #Alzheimerdisease #FDAapproval https://t.co/u71iDguGxY https://t.co/aEMIYmsALk
-
The recent #FDAapproval of cabozantinib for select patients with well-differentiated pNETs and epNETs was based on results from the phase 3 CABINET trial. @US_FDA https://t.co/QIN3Bd21OM https://t.co/nFGjcNznF5